Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs Novo Nordisk A/S — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.57, while Novo Nordisk A/S trades at $49.86 (market cap $214.94B). The key difference: Novo Nordisk A/S pays a 3.67% dividend while Bitwise Crypto Industry Innovators ETF pays none. Which is the better fit depends on your goals.
| BITQ | NVO | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $71.70 |
52-Week Low | $16.74 | $35.29 |
Market Cap | — | $214.94B |
Enterprise Value | — | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.
The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
